<DOC>
	<DOCNO>NCT00861692</DOCNO>
	<brief_summary>The purpose study collect data clinical management Argatroban patient suspect confirmed heparin-induced thrombocytopenia Type II , without ongoing thrombosis require parenteral antithrombotic therapy</brief_summary>
	<brief_title>Clinical Management Argatroban Patients With Heparin Induced Thrombocytopenia Type II</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Argatroban</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Subjects age &gt; = 18 year Females child bear potential must negative urine pregnancy test prior entry study Patients suspect confirm heparininduced thrombocytopenia Type II , without ongoing thrombosis require parenteral anticoagulation Signed write informed consent subject , subject unable , consent seek family member , trust person nominate subject legal representative Uncontrolled bleed Severe hepatic impairment ( ChildPugh Class C ) Hypersensitivity argatroban excipients ( sorbitol ethanol ) Pregnancy ( exclusion routine urine test ) Lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Argatroban</keyword>
	<keyword>heparin induce thrombocytopenia ( HIT )</keyword>
	<keyword>direct thrombin inhibitor ( DTI )</keyword>
</DOC>